Hepatitis E masquerading as drug-induced liver injury

Hepatology

Volumn 56, Issue 6, 2012, Pages 2420-2423

  Chen, Emerson Y ^a   Baum, Karl ^b   Collins, William ^c   Löve, Arthur ^d   Merz, Michael ^c   Olafsson, Sigurdur ^d   Björnsson, Einar S ^d   Lee, William M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Klinik Hennigsdorf   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FINGOLIMOD; GAMMA GLUTAMYLTRANSFERASE; VIRUS RNA;

ABNORMAL FECES; ADULT; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXHAUSTION; FATIGUE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; JAUNDICE; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RETREATMENT; SIDE EFFECT; TOXIC HEPATITIS; ULTRASOUND; URINE COLOR; VIRUS DETECTION; VIRUS LOAD;

ADULT; DIAGNOSIS, DIFFERENTIAL; DRUG-INDUCED LIVER INJURY; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; MALE; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RNA, VIRAL; SPHINGOSINE;

EID: 84870513832     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26158     Document Type: Article

References (9)

1. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32: 55-68.
2. Benichou C. Criteria of drug-induced liver disorders. report of an international consensus meeting. J Hepatol 1990; 11: 272-276.
3. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs. II. an original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336.
4. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. HEPATOLOGY 2010; 51: 2117-2126.
5. Kamar N, Selves J, Mansuy JM, Ouezzani L, Peron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358: 811-817.
6. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E. Lancet 2012; 379: 2477-2488.
7. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011; 141: 1665-1672.e1-9.
8. Gupta P, Jagya N, Pabhu SB, Durgapal H, Acharya SK, Panda SK. Immunohistochemistry for the diagnosis of hepatitis E virus infection. J Viral Hepatol 2012; 19: e177-183.
9. Danan G, Benichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.